Pimecrolimus offers effective, safe option for hand dermatitis
Pimecrolimus offers effective, safe option for hand dermatitis
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.